# A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

> **NCT07321951** · PHASE2 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Moderate-to-severe Atopic Dermatitis

## Interventions

- **DRUG:** SHR-1819 Injection
- **DRUG:** SHR-1819 Injection Blank Preparation

## Key facts

- **NCT ID:** NCT07321951
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2027-06
- **Final completion:** 2027-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321951, "A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07321951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*